Is Rinvoq Approved for Rheumatoid Arthritis?
Yes, Rinvoq (upadacitinib) is FDA-approved for adults with moderately to severely active rheumatoid arthritis (RA) who have had an inadequate response or intolerance to methotrexate. It's a selective JAK inhibitor taken as a once-daily oral tablet, often used alone or with methotrexate or other nonbiologic DMARDs.[1][2]
How Does Rinvoq Work for RA?
Rinvoq blocks Janus kinase enzymes (JAK1 primarily), interrupting inflammatory signaling pathways in RA. This reduces joint pain, swelling, and damage progression. Clinical trials like SELECT showed 70-76% of patients achieving ACR20 response (20% symptom improvement) at week 12, versus 36% on placebo.[2][3]
Who Can Take Rinvoq for RA?
Approved for adults 18+ with moderate-to-severe RA. Not for children. Prescribers screen for tuberculosis risk, infections, and malignancies due to immunosuppression. Avoid in active infections or with strong CYP3A4 inhibitors/inducers.[1][4]
Common Side Effects and RA Patient Concerns
Upper respiratory infections (14%), nausea (6%), and elevated liver enzymes occur most. Serious risks include infections (herpes zoster, pneumonia), blood clots, heart events, cancers, and gastrointestinal tears—black box warnings apply. RA patients report monitoring fatigue and injection-site alternatives, but Rinvoq avoids needles.[2][5]
How Does Rinvoq Compare to Other RA Treatments?
| Treatment | Type | Dosing | ACR20 Response (Week 12) | Key Edge |
|-----------|------|--------|---------------------------|----------|
| Rinvoq | Oral JAK inhibitor | 15 mg daily | 71% monotherapy[3] | Pill convenience |
| Xeljanz (tofacitinib) | Oral JAK inhibitor | 5 mg twice daily | 65%[6] | Similar efficacy; Rinvoq dosed once |
| Humira (adalimumab) | Injectable TNF blocker | Every 2 weeks | 62%[7] | Broader approvals; higher infection risk profile |
| Olumiant (baricitinib) | Oral JAK inhibitor | 2-4 mg daily | 70%[8] | Comparable; Rinvoq stronger on physical function scores |
Rinvoq often shows faster onset than biologics in head-to-head data.[3]
Rinvoq Dosage and Cost for RA
Start at 15 mg once daily; max 30 mg for inadequate response. Average wholesale price: $6,200/month (15 mg), but copay cards cap at $5-$25 for insured patients.[9] Medicare Part D coverage varies.
Patent Status and When Generics Might Arrive
AbbVie's core patents on Rinvoq expire in 2033 in the US, with formulation patents to 2037. No Paragraph IV challenges listed yet on DrugPatentWatch.com, delaying generics until at least 2033.[10]
Sources
[1]: FDA Label - Rinvoq (2023) https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/210918s017lbl.pdf
[2]: Rinvoq.com - RA Indication
[3]: SELECT Phase 3 Trials (NEJM 2018) https://www.nejm.org/doi/full/10.1056/NEJMoa1803978
[4]: RA Guidelines (ACR 2021)
[5]: Postmarketing Safety Data (FDA FAERS)
[6]: Xeljanz Trials (NEJM 2013)
[7]: Humira ARMADA Trial
[8]: Olumiant RA Trials
[9]: GoodRx Pricing (2024)
[10]: DrugPatentWatch.com - Rinvoq https://www.drugpatentwatch.com/p/tradename/RINVOQ